

**ANNOUNCEMENT OF THE SUMMARY OF THE MINUTES OF MEETING
ANNUAL GENERAL MEETING OF SHAREHOLDERS
PT PYRIDAM FARMA TBK.**

Board of Directors of PT Pyridam Farma Tbk. (“**Company**” or “**we**”) hereby informs the Shareholders of the Company, that the Company will hold its Annual General Meeting of Shareholders (“**AGMS**” or “**Meeting**”), in accordance with Financial Services Authority (Otoritas Jasa Keuangan “**OJK**”) Regulation No. 14 of 2025 concerning the Electronic Conduct of General Meetings of Shareholders, Bondholders’ Meetings, and Sukukholders’ Meetings, and OJK Regulation No. 15/POJK.04/2020 concerning the Planning and Conduct of General Meetings of Shareholders of Public Companies, as follows:

A. The Meeting was held as follows:

Day/Date : Thursday, June 11, 2026
Time : 2:40 p.m. Jakarta’s time to 3:55 p.m. Jakarta’s time
Venue : Financial Hall – Graha CIMB Niaga, 2nd Floor
Jl. Jenderal, Sudirman Kav. 58, South Jakarta 12190, Indonesia.

Meeting Agenda:

1. Approval of the Annual Report, Sustainability Report, and Ratification of the Company's Financial Statements for the financial year which ended on December 31, 2025, as well as granting full release and discharge (*volledig acquit et de charge*) to the members of the Board of Directors and the Board of Commissioners for the management and supervision actions carried out during the financial year which ended on December 31, 2025.
 2. Determination on the utilization of the Company's Net Profit/Net Loss for the financial year which ended on December 31, 2025.
 3. Determination of Remuneration for Members of the Board of Directors and the Board of Commissioners of the Company for the 2026 Financial Year.
 4. Determination of a Public Accounting Firm to audit the Company's Consolidated Financial Statements for the financial year ending on December 31, 2026.
 5. Reporting on the Realization of the Use of Proceeds from the Public Offering of Pyridam Farma Continuous Bonds I Phase III Year 2024, Pyridam Farma Continuous Bonds II Phase I Year 2025, and the Limited Public Offering to Shareholders for Capital Increase with Pre-emptive Rights I and Issuance of Series 1 Warrants.
 6. Approval of amendments to the Company's Articles of Association, specifically the adjustment of the formulation regarding the Company's Business Activities as set forth in the provisions of Article 3 of the Company's Articles of Association concerning the Purposes and Objectives as well as Business Activities of the Company against the Regulation of the Central Bureau of Statistics Number 7 of 2025 concerning the Indonesia Standard Industrial Classification (KBLI 2025).
 7. Approval of Changes to the Composition of the Company's Management.
- B. Members of the Board of Directors and Board of Commissioners of the Company who were present, either physically or electronically, at the Meeting:**

Board of Directors:

President Director : LEE YAN GWAN
Director : YENFRINO GUNADI
Director : BEDJO STEFANUS

HEAD OFFICE

Sinar Mas Land Plaza Sudirman,
12th Floor, Jl. Jend. Sudirman Kav. 21,
Jakarta 12920 - Indonesia

P +62-21-5099-1067

FACTORY

Hanjawar, Pacet,
Cianjur 43253 - Indonesia

P +62-263-580-833
F +62-263-582-290

Director : ANTES EKO PRASETIO
Director : SINTA LESTARI NINGSIH

Board of Commissioners:

President Commissioner : ROBBY YULIANTO
Commissioner : dr. WIDJANARKO BRODOSAPUTRO
Independent Commissioner : MAURA LINDA SITANGGANG
Independent Commissioner : CHARLES D. MARPAUNG

- C. The Meeting was attended by **7,596,529,353** shares carrying valid voting rights, representing **67.60%** of the total issued shares of the Company with valid voting rights.
- D. During the Meeting, each shareholder or their proxy was given the opportunity to raise questions and/or express opinions regarding each item on the Meeting agenda.
- E. The voting procedures at the Meeting were as follows:
Meeting resolutions were adopted through deliberation to reach a consensus. If any shareholder or proxy voted against a proposal or abstained from voting, the resolution was put to a vote.
- F. The number of shareholders/proxies who raised questions and/or expressed opinions, as well as the voting results for each agenda item of the Annual General Meeting of Shareholders, were as follows:

Agenda AGMS	Number of Shareholders/ Proxies Raising Questions	Voting Results		
		Agree	Against	Abstain/Blank
1	2	7.593.249.652 shares (99,9568% of shares present)	530.001 shares (0,0070% of shares present)	2.749.700 shares (0,0362% of shares present)
2	0	7.593.779.652 shares (99,9638% of shares present)	1 share (0% of shares present)	2.749.700 shares (0,0362% of shares present)
3	0	7.593.779.652 shares (99,9638% of shares present)	1 share (0% of shares present)	2.749.700 shares (0,0362 of shares present)
4	0	7.593.779.652 shares (99,9638% of shares present)	1 share (0% of shares present)	2.749.700 shares (0,0362% of shares present)
5	0	7.593.779.652 shares	1 share (0% of shares present)	2.749.700 shares

HEAD OFFICE

Sinar Mas Land Plaza Sudirman,
12th Floor, Jl. Jend. Sudirman Kav. 21,
Jakarta 12920 - Indonesia

P +62-21-5099-1067

FACTORY

Hanjawar, Pacet,
Cianjur 43253 - Indonesia

P +62-263-580-833

F +62-263-582-290

		(99,9638% of shares present)		(0,0362% of shares present)
6	0	7.593.779.652 shares (99,9638% of shares present)	1 share (0% of shares present)	2.749.700 shares (0,0362% of shares present)
7	0	7.593.779.652 shares (99,9638% of shares present)	1 share (0% of shares present)	2.749.700 shares (0,0362% of shares present)

G. At the Meeting, the following resolutions were duly adopted by majority vote:

I. First Agenda

1. To approve the Company's Annual Report and Sustainability Report and to ratify the Company's Financial Statements for the financial year ended December 31, 2025.
2. Following the approval of the Company's Annual Report, including the Sustainability Report and the Supervisory Report of the Board of Commissioners for the financial year ended December 31, 2025, as well as the ratification of the Company's Consolidated Financial Statements for the financial year ended December 31, 2025, which were audited by Purwanto, Susanti and Surja Public Accounting Firm, a member firm of Ernst & Young, and which, in all material respects, fairly present the financial position of the Company, the Meeting granted a full release and discharge (volledig acquit et de charge) to all members of the Board of Directors and the Board of Commissioners for their management and supervisory actions carried out during the financial year ended December 31, 2025, insofar as such actions do not constitute criminal acts and are reflected in the Company's Annual Report, Sustainability Report, and Consolidated Financial Statements for the financial year ended December 31, 2025.
3. To grant authority, with the right of substitution, to the Board of Directors of the Company, acting jointly or individually, to take all actions necessary in connection with the foregoing resolutions, including but not limited to preparing, signing, and submitting all required documents, stating such resolutions in a separate notarial deed, and subsequently notifying the relevant authorities of the Company's Annual Report in accordance with the applicable laws and regulations.

II. Second Agenda

To approve the recording of a net loss of IDR 379,670,109,302 (three hundred seventy-nine billion six hundred seventy million one hundred nine thousand three hundred two Rupiah) for the 2025 financial year, and not to allocate any profit to statutory reserves or distribute any dividends in respect of the 2025 financial year.

HEAD OFFICE

Sinar Mas Land Plaza Sudirman,
12th Floor, Jl. Jend. Sudirman Kav. 21,
Jakarta 12920 - Indonesia

P +62-21-5099-1067

FACTORY

Hanjawar, Pacet,
Cianjur 43253 - Indonesia

P +62-263-580-833

F +62-263-582-290

III. Third Agenda

To grant authority and power to the Board of Commissioners of the Company to determine the amount of salaries or honoraria and other allowances for the members of the Board of Commissioners and the Board of Directors of the Company for the financial year ending December 31, 2026, based on a resolution of the Board of Commissioners, including the aggregate amount of salaries, honoraria, tantiem, and other benefits for the Board of Directors and the Board of Commissioners, while taking into account the Company's financial condition and performance.

IV. Fourth Agenda

To grant authority to the Board of Commissioners to appoint the Public Accounting Firm that will audit the Company's Financial Statements for the financial year ending December 31, 2026, taking into consideration the proposal of the Board of Commissioners and the recommendation of the Company's Audit Committee, and to authorize the Board of Directors to determine the fees of such public accountant and other related terms and conditions, considering that the Company still requires time to monitor and evaluate performance and to assess prospective public accountants to be appointed based on input from the Board of Commissioners and the Audit Committee, as well as other objective considerations deemed necessary in making such decision.

V. Fifth Agenda

Approve the Public Offering Report of Continuous Bonds I Pyridam Farma Phase III Year 2024 as of 31 December 2025 in the amount of Rp321,594,822,184 (three hundred twenty-one billion five hundred ninety-four million eight hundred twenty-two thousand one hundred eighty-four rupiah), as referred to in the Report on the Realization of the Use of Funds from the Continuous Bond Public Offering I Pyridam Farma Phase III Year 2024, with letter number: 009/PYFA-CS/I/2026 dated 15 January 2026, the Public Offering Report of Continuous Bonds II Pyridam Farma Phase I Year 2025 as of 31 December 2025 in the amount of Rp400,000,000,000 (four hundred billion rupiah), as referred to in the Report on the Realization of the Use of Funds from the Continuous Bond Public Offering II Pyridam Farma Phase I Year 2025, with letter number: 011/PYFA-CS/I/2026 dated 15 January 2026 and letter number: 011a/PYFA-CS/II/2026 dated 4 February 2026, and the Limited Public Offering Report to Shareholders through Capital Increase by Granting Pre-emptive Rights I and Issuance of Series I Warrants, whereby the Company has completed the realization of the use of all proceeds from the conversion of Series I Warrants into shares as of 31 December 2025 in the amount of Rp10,235,200 (ten million two hundred thirty-five thousand two hundred rupiah), as referred to in the Report on the Realization of the Use of Funds from the Limited Public Offering to Shareholders through Issuance of Series I Warrants, with number: 010/PYFA-CS/I/2026 dated 15 January 2026.

VI. Sixth Agenda

1. To approve the amendment to the Company's Articles of Association, namely the adjustment of the wording related to the Company's business activities as stipulated in Article 3 of the Company's Articles of Association concerning the Company's Purpose and Objectives and Business Activities, to align with Statistics

HEAD OFFICE

Sinar Mas Land Plaza Sudirman,
12th Floor, Jl. Jend. Sudirman Kav. 21,
Jakarta 12920 - Indonesia

P +62-21-5099-1067

FACTORY

Hanjawar, Pacet,
Cianjur 43253 - Indonesia

P +62-263-580-833

F +62-263-582-290

Indonesia (Badan Pusat Statistik) Regulation No. 7 of 2025 on the Standard Classification of Indonesian Business Fields (KBLI 2025), as follows:

OBJECTIVES AND PURPOSES AND BUSINESS ACTIVITIES

ARTICLE 3

The objectives and purposes of the Company, as well as its business activities in accordance with Statistics Indonesia Regulation No. 7 of 2025 concerning the Indonesian Standard Classification of Business Fields (KBLI 2025) (hereinafter referred to as the “KBLI”), are as follows:

1. The Company’s Main Business Activities are as follows:

A. CLEANING MATERIALS AND PRODUCTS INDUSTRY

To carry out business activities in the manufacture of cream soap, dishwashing soap; detergents and other household cleaning agents; paper, cotton wool, textiles, and the like coated with soap or detergent, such as wet wipes; crude glycerol; surfactant preparations such as washing powder, both solid and liquid, dishwashing detergents, and fabric softeners; cleaning and polishing products such as air fresheners and room deodorizers, artificial wax and processed wax, polish and creams for leather goods, wood polish and creams, glass and metal polish, and scouring pastes and powders, including paper, pads, and others coated with polishing pastes and powders; antiseptic and household disinfectant products.

B. HUMAN COSMETICS INDUSTRY, CONTACT LENS SOLUTIONS

To carry out business activities in the manufacture of human cosmetics, such as hair care products (shampoo, hair curling and straightening products, etc.); nail care products (manicure and pedicure); skin care products (sunscreen creams or lotions and tanning products); personal hygiene products (cosmetic soap, bath soap, antiseptic bath soap, external intimate hygiene products, deodorants, bath salts, etc.); shaving products; decorative cosmetics such as facial makeup, eye makeup, perfumes, nail makeup, and hair makeup, including hair dye; toothpaste and oral hygiene products, including cosmetic teeth whitening products; and contact lens solutions.

C. HUMAN PHARMACEUTICAL RAW MATERIALS INDUSTRY

To carry out business activities in the manufacture and processing of pharmaceutical raw materials and supporting materials for human use derived from chemicals, natural resources, animals, and plants, including biological products such as medicinal substances, including antisera and other blood fractions, vaccines, and homeopathic preparations, active pharmaceutical substances (antibiotics, vitamins, salicylic acid, acetylsalicylic acid, etc.) for pharmaceutical use, blood processing, chemically pure sugar, pharmaceutical-grade salts, gland processing, and gland extraction.

HEAD OFFICE

Sinar Mas Land Plaza Sudirman,
12th Floor, Jl. Jend. Sudirman Kav. 21,
Jakarta 12920 - Indonesia

P +62-21-5099-1067

FACTORY

Hanjawar, Pacet,
Cianjur 43253 - Indonesia

P +62-263-580-833

F +62-263-582-290



D. HUMAN PHARMACEUTICAL PRODUCTS INDUSTRY

To carry out business activities in the manufacture and processing of finished pharmaceutical products, health supplements/food supplements, and quasi drugs for human use in the form of tablets, capsules, ointments, powders, solutions, parenteral solutions, suspensions, hormonal contraceptives; production of radiopharmaceuticals; and pharmaceutical biotechnology products.

E. INDUSTRY OF MEDICAL DIAGNOSTIC DEVICES, BANDAGES, GAUZE, AND OTHER HEALTH SUPPORT PRODUCTS

To carry out business activities in the manufacture and processing of medical devices for diagnostic purposes and other products under subclass 2011. This includes external contraceptive products; medical diagnostic devices such as pregnancy test kits and blood glucose test kits; medical cotton, cosmetic cotton, cotton buds, bandages, medical gauze, plasters; nasal wash products, and personal lubricants.

F. TRADITIONAL MEDICINE PRODUCTS INDUSTRY FOR HUMAN USE

To carry out business activities in processing various traditional medicine products derived from natural resources in raw or minimally processed form from plants, animals, microorganisms, minerals, or their combinations, in forms such as powders, instant powders, slices, pills, dodol/gel-like preparations, pills, pastes, tablets, capsules, liquids, solutions, emulsions, suspensions, effervescent forms, films, strips, gummy chewables, ointments, lotions, creams, gels, aerosol external medicines, patches, and suppositories; including herbal beverages and health supplements that are not classified as pharmaceutical products.

G. GLASS LABORATORY AND HEALTH EQUIPMENT INDUSTRY

To carry out business activities in the manufacture of various laboratory and medical equipment made of glass, including clinical laboratory tools for diagnostic purposes such as test tubes for biological samples (blood, urine, saliva), as well as non-clinical laboratory and health equipment such as serum bottles/infusion bottles, ampoules, test tubes, measuring tubes, microscope slides, cuvettes, and desiccators.

H. OTHER PLASTIC PRODUCTS INDUSTRY

To carry out business activities in the manufacture of plastic goods not classified under subclass 2220, such as

- office/educational equipment; plastic medical/laboratory equipment such as infusion bags and tubing;
- cellophane films or sheets;
- synthetic stone made of plastic; plastic signage (non-electrical);
- various plastic goods such as headgear, sealing equipment, lighting components, clothing items (if only sealed or assembled, not sewn), furniture accessories, sculptures, plastic adhesive tapes, plastic wall coverings, durable plastic shoes, cigar and cigarette holders, combs, hair curlers, and other plastic items.

HEAD OFFICE

Sinar Mas Land Plaza Sudirman,
12th Floor, Jl. Jend. Sudirman Kav. 21,
Jakarta 12920 - Indonesia

P +62-21-5099-1067

FACTORY

Hanjawar, Pacet,
Cianjur 43253 - Indonesia

P +62-263-580-833

F +62-263-582-290

This group also includes processing and finishing activities of plastic goods such as metal coating or other surface treatment and painting (excluding plastic automotive parts and accessories).

I. WHOLESALE TRADE OF MEDICAL AND LABORATORY EQUIPMENT FOR HUMAN USE

To carry out business activities including wholesale trade of laboratory equipment, medical, surgical, orthopedic devices, and similar equipment for human use.

J. WHOLESALE TRADE OF PHARMACEUTICAL PRODUCTS FOR HUMAN USE

To carry out business activities in the wholesale distribution of pharmaceutical preparations, including medicinal raw materials, natural medicinal substances, cosmetics, quasi drugs, health supplements, medicines, and traditional medicines intended for human use.

N. TECHNICAL TESTING SERVICES

To carry out business activities including:

- sampling activities to determine material or process characteristics;
- calibration/metrology activities in measurements of temperature, mass, volume, pressure, force, torque, flow, hardness, density, length, electricity, magnetism, time, frequency, acoustics, vibration, photometry, radiometry, and ionizing radiation analytical instruments; testing covering physical, mechanical, chemical, biological, microbiological, electrical, nuclear, visual/checklist, design model/prototype, forensic or other analyses across various materials/products in industries such as manufacturing, trade, energy, construction, transportation, telecommunications, pharmaceuticals, food, agriculture, forestry, and environmental quality (water, air, soil, and other indicators);
- periodic conformity assessment of laboratory physical characteristics, composition, and performance;
- periodic testing or calibration of medical equipment;
- quarantine testing of animals, plants, and fisheries;
- marine testing;
- testing of machinery and ionizing radiation equipment such as survey meters, contamination meters, dosimeters, and X-ray multimeters;
- calibration activities for industrial instruments such as machines, equipment, and measuring tools;
- electronics and other technology testing.

This group also includes calibration/metrology and certification activities to verify and validate measuring instruments or calibration tools to ensure their accuracy and reliability.

HEAD OFFICE

Sinar Mas Land Plaza Sudirman,
12th Floor, Jl. Jend. Sudirman Kav. 21,
Jakarta 12920 - Indonesia

P +62-21-5099-1067

FACTORY

Hanjawar, Pacet,
Cianjur 43253 - Indonesia

P +62-263-580-833

F +62-263-582-290

2. Supporting Business Activities Of The Company are:

A. HOLDING COMPANY ACTIVITIES

To carry out activities of holding companies, such as units that hold assets (owning and managing equity interests) in one or more subsidiaries and are only responsible as the owner of such subsidiaries. Companies in this group do not provide other services to companies whose equity is held by the holding company; for example, the holding company does not manage or operate other units. Such holding companies may conduct activities such as control, financial consolidation, and being responsible for the activities of each subsidiary, but not the active management of those subsidiaries, for example, financial conglomerate holding companies.

B. OTHER MANAGEMENT AND BUSINESS CONSULTING ACTIVITIES

To carry out activities including advisory, guidance, and operational assistance in business and other organizational and management matters, such as strategic and organizational planning; financial decision-making; planning objectives and policies; human resource planning, practices, and policies; production scheduling and control planning. The provision of these services may include advisory assistance and operational support across various management functions, agronomist and agricultural economist consulting in agriculture and related fields, design of accounting methods and procedures, cost accounting programs, budget control procedures, provision of advice and assistance to businesses and public services in planning, organization, efficiency, and supervision, management information services, occupational health and safety consulting such as risk identification and documentation, and others.

2. To grant authority, with substitution rights, to the Board of Directors of the Company, jointly or individually, to take all actions in connection with the above resolutions, including but not limited to preparing, signing, and submitting all required documents, stating them in a separate notarial deed before a Notary, and subsequently applying for approval of amendments to the Company's Articles of Association to the competent authorities in accordance with applicable laws and regulations.

VII. Seventh Agenda

1. To accept the resignation of Mr. Robby Yulianto as President Commissioner of the Company, with appreciation for his services and performance in carrying out the supervisory duties of the Company.
2. To appoint Mr. Widjanarko Brotosaputro as President Commissioner of the Company, effective as of the closing of this Meeting and until the end of his term of office, continuing the remaining term of the replaced member of the Board of Commissioners in accordance with Article 32 paragraph (5) of the Company's Articles of Association, without prejudice to the right of the General Meeting of Shareholders to dismiss him at any time.
3. To determine the composition of the Company's Board of Commissioners, effective as of the closing of this Meeting until the end of the respective terms of office at the Annual General Meeting of Shareholders to be held in 2030, without

HEAD OFFICE

Sinar Mas Land Plaza Sudirman,
12th Floor, Jl. Jend. Sudirman Kav. 21,
Jakarta 12920 - Indonesia

P +62-21-5099-1067

FACTORY

Hanjawar, Pacet,
Cianjur 43253 - Indonesia

P +62-263-580-833

F +62-263-582-290

prejudice to the right of the General Meeting of Shareholders to dismiss them at any time, as follows:

1. Mr. dr. WIDJANARKO BRODOSAPUTRO as President Commissioner;
 2. Mr.CHARLES D. MARPAUNG as Independent Commissioner; and
 4. Mrs. MAURA LINDA SITANGGANG as Independent Commissioner.
4. To grant authority, with substitution rights, to the Board of Directors of the Company, jointly or individually, to take all necessary actions in connection with the above resolutions, including but not limited to preparing, signing, and submitting all required documents, stating such resolutions in a separate notarial deed before a Notary, and subsequently notifying the changes in the Company's management structure to the relevant authorities in accordance with applicable laws and regulations.

Jakarta, June 15, 2026

**Board of Directors
PT Pyridam Farma Tbk.**

HEAD OFFICE

Sinar Mas Land Plaza Sudirman,
12th Floor, Jl. Jend. Sudirman Kav. 21,
Jakarta 12920 - Indonesia

P +62-21-5099-1067

FACTORY

Hanjawar, Pacet,
Cianjur 43253 - Indonesia

P +62-263-580-833
F +62-263-582-290